Clinical Report: Evaluating Post-Surgical Radiotherapy in ESCC
Overview
This meta-analysis evaluates the efficacy of postoperative radiotherapy (PORT) in patients with resected esophageal squamous cell carcinoma (ESCC), demonstrating significant improvements in overall survival (OS) and disease-free survival (DFS) compared to surgery alone. PORT reduces locoregional recurrence but is associated with increased acute toxicity.
Background
Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is a leading cause of cancer-related mortality globally. Despite radical surgery being the primary treatment, high postoperative recurrence rates necessitate effective adjuvant therapies. The role of postoperative radiotherapy (PORT) remains debated, with previous studies yielding conflicting results regarding its impact on survival outcomes.
Data Highlights
Outcome
Hazard Ratio (HR) / Odds Ratio (OR)
95% Confidence Interval (CI)
P-value
Overall Survival (OS)
0.74
0.69–0.80
<0.001
Disease-Free Survival (DFS)
0.62
0.58–0.67
<0.001
Locoregional Recurrence (LRR)
0.30
0.27–0.34
<0.001
Distant Metastasis (DM)
1.01
0.92–1.11
0.85
Grade ≥3 Acute Toxicity
2.45
1.89–3.18
<0.001
Key Findings
PORT significantly improved overall survival (OS) with a hazard ratio (HR) of 0.74.
PORT also improved disease-free survival (DFS) with an HR of 0.62.
PORT reduced locoregional recurrence (LRR) with an odds ratio (OR) of 0.30.
No significant effect on distant metastasis (DM) was observed (OR = 1.01).
PORT was associated with a higher incidence of grade ≥3 acute toxicity (OR = 2.45).
Clinical Implications
The findings indicate that PORT may improve survival outcomes in patients with resected ESCC. However, clinicians should be aware of the increased risk of acute toxicity associated with PORT.
Conclusion
PORT significantly enhances survival outcomes in patients with radically resected ESCC, although it is linked to increased acute toxicity.
